User:Zben: Difference between revisions
No edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
Ben Zeskind earned a PhD in Bioengineering from MIT's Biological Engineering | == Ben Zeskind, PhD, MBA == | ||
Ben Zeskind earned a PhD in Bioengineering from MIT's Biological Engineering Department, awarded June 9, 2006. His work resulted in a first-author publication in Nature Methods: [http://www.nature.com/nmeth/journal/v4/n7/abs/nmeth1053.html Nucleic acid and protein mass mapping by live-cell deep-ultraviolet microscopy], two issued U.S. Patents: "Method and apparatus for UV imaging" (U.S. Patent # [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7,491,943.PN.&OS=PN/7,491,943&RS=PN/7,491,943 7,491,943]), and "Method and apparatus for generating a circularly polarized illumination" (U.S. Patent # [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7,335,874.PN.&OS=PN/7,335,874&RS=PN/7,335,874 7,335,874]), and was profiled in the Whitehead Institute's [http://www.wi.mit.edu/news/paradigm/fall_2007/weigh.html Paradigm Magazine]. He subsequently earned an MBA at Harvard Business School, graduating as a Baker Scholar -- the highest award for distinction. He has authored a contributed paper on [http://journals.cambridge.org/action/displayAbstract?aid=1948344 Deep Ultraviolet Microscopy and its Application to Cancer Immunology], and co-authored [http://www.translational-medicine.com/content/6/1/81 A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers."] He is the founder and CEO of [http://www.immuneering.com Immuneering Corporation], a company developing groundbreaking patient stratification technology to pre-identify patients who will respond to specific therapies, and ultimately make it easier to develop therapies that trigger an immune response to eliminate a patient's cancer. Immuneering was profiled in a recent article in Mass High Tech, [http://www.masshightech.com/stories/2009/02/09/weekly7-Immuneering-tests-another-path-for-personalized-medicine.html Immuneering tests another path for personalized medicine.] | |||
Latest revision as of 16:37, 17 February 2009
Ben Zeskind, PhD, MBA
Ben Zeskind earned a PhD in Bioengineering from MIT's Biological Engineering Department, awarded June 9, 2006. His work resulted in a first-author publication in Nature Methods: Nucleic acid and protein mass mapping by live-cell deep-ultraviolet microscopy, two issued U.S. Patents: "Method and apparatus for UV imaging" (U.S. Patent # 7,491,943), and "Method and apparatus for generating a circularly polarized illumination" (U.S. Patent # 7,335,874), and was profiled in the Whitehead Institute's Paradigm Magazine. He subsequently earned an MBA at Harvard Business School, graduating as a Baker Scholar -- the highest award for distinction. He has authored a contributed paper on Deep Ultraviolet Microscopy and its Application to Cancer Immunology, and co-authored A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers." He is the founder and CEO of Immuneering Corporation, a company developing groundbreaking patient stratification technology to pre-identify patients who will respond to specific therapies, and ultimately make it easier to develop therapies that trigger an immune response to eliminate a patient's cancer. Immuneering was profiled in a recent article in Mass High Tech, Immuneering tests another path for personalized medicine.
